ABSTRACT Commercial layer hens reared on multiage hen complexes are vaccinated during pullet rearing to combat production losses due to the bacteria Mycoplasma gallisepticum (MG). In this study, the potential to in ovo vaccinate layer chickens against MG was investigated. Layer embryos were administered a dosage of a live attenuated strain F MG (FMG) vaccine at 18 d of incubation and raised for 6 wk for initial post-hatch evaluation in 2 replicate trials. Treatments included control non-injected eggs, eggs injected with diluent, a non-diluted dosage, a 10 −2 dilution, a 10 −4 dilution, and a 10 −6 dilution. A subset of chicks were swabbed for detection of FMG in the trachea at hatch. At 6 wk of age, birds were swabbed again for FMG detection and a blood sample was tested for MG antibody production. Hatch was depressed in the nondiluted dose group (P < 0.0001). Strain F MG was detected at hatch in the trachea in each FMG injection treatment, with decreasing numbers of positive chicks in the lower dosage groups. Mortality during the first 2 wk post-hatch was 3.5% (trial 1) and was 11.7% (trial 2) in the 10 −6 dilution treatment, with all other FMG treatments experiencing a high rate of mortality (>50%). Birds in the in ovo FMG treatments had detectable FMG and antibody production at 6 wk. There were no differences in percentage positive birds (P > 0.3 for all tests) or ELISA titers (P = 0.079) between the FMG treatments. Body weight at 6 wk of age was diminished with increasing FMG dose (P < 0.0001). The lowest dose tested was found to be the most practical, causing the least mortality, least weight loss, and a humoral immune response in the majority of the birds. Further work is needed to evaluate how this in ovo vaccine, promoting immunity earlier, would compare to a standard post-hatch vaccination against an MG challenge scenario through a lay cycle.
INTRODUCTION
Mycoplasma gallisepticum (MG) is considered one of the most costly avian diseases to the commercial layer poultry industry which is predominantly due to egg production losses (Mohammed et al., 1987; Levisohn and Kleven, 2000) . The layer chicken industry, having multi-age bird complexes, is unable to eradicate MG where the bacteria is transmitted from older to younger birds (Olesiuk et al., 1967; Levisohn and Kleven, 1981; Evans et al., 2005) . In order to combat egg production losses resulting from these field strain MG infections, layer chickens are vaccinated against MG during pullet rearing before the start of lay (Levisohn and Kleven, 1981 ) using a bacterin, fowl pox vectored MG vaccine, or live MG vaccines of strains 6/85, ts-11, or F (Abd-El-Motelib and Kleven, 1993; Whithear, 1996; Hy-Line International, 2013) . Live MG vaccines (particularly strain F), while helpful in the face of an MG challenge, are a detriment to production when compared to MG-clean birds (Carpenter et al., 1981; Branton et al., 1988; Abd-El-Motelib and Kleven, 1993) .
in ovo vaccination is a relatively new alternative vaccination method that has potential for use against MG infection. By introducing the MG vaccine further from the initiation of photostimulation through in ovo MG injection, the detrimental effects of the vaccine may be less pronounced in comparison to that of a standard MG vaccination. Additionally, in ovo vaccination has the prospect of reducing labor costs, stress on the birds, and vaccine usage.
El Safty et al. (2005) investigated the use of in ovo vaccination for MG. Their report provided promising results. However, a limited sample size and information (such as no dosage values) left many unanswered 3860 questions. Thus, a preliminary trial (48 embryos per treatment) was conducted by Elliott et al. (2017) to determine if chicken embryos could survive an administration of the MG F strain, considered the most virulent live attenuated MG vaccine, given at 18 d of incubation. It was reported that the lowest hatch (60% of vaccinated layer chicken embryos) occurred in response to a high dosage (10 6 colony-forming units [CFU] per dose) of a live attenuated strain F MG (FMG) vaccine ordinarily administered post-hatch. Dilutions of the high dosage improved hatch (vaccine dosages at 10 −4 and 10 −6 dilutions) to a level comparable to non-injected controls. Several chicks were noted to exhibit breathing distress in the 2 highest doses, which led to doubts concerning the survival of the chicks beyond the hatching period and questions as to the immune response of these birds to the MG vaccine. The preliminary study warranted a larger sample size in order to confirm hatch success and to determine the in ovo-administered vaccine's effect on post-hatch survival, growth, and immunity.
Few studies have involved the injection of MG into embryonated chicken eggs, with subsequent evaluations of hatchability and post-hatch responses. Roberts and Olesiuk (1966) and Power and Jordan (1976) found varied post-hatch survival rates in chickens that had been injected with MG during incubation. Roberts and Olesiuk (1966) injected a 0.1 mL volume of a 10 −5 dilution of FMG that had been passaged 54 times in broth into either the yolk sac of embryos incubated for 7 d or intravenously into embryos at 14 d of incubation, with 223 bacteria injected into each embryo. Power and Jordan (1976) injected the yolk sacs of specific pathogen free chicken embryos at 18 d of incubation with a 0.1 mL volume of 108 CFU dose of MG of either strain S6 (9 passages or 150 passages) or strain A514 (reported cultured repeatedly in the lab). The reported mortality percentages from these studies ranged from 0 to 80.5 during the first week post-hatch. Their results varied based upon the strain of MG, the passage level of the MG, and the age of the embryo when injected. Roberts and Olesiuk (1966) additionally found antibody production against MG in approximately 40 to 90% of the surviving birds at 4 wk of age.
Although bird survival is dependent on the strain of MG and the attenuation of the bacteria, these past studies have shown that it is possible for embryonated chicken eggs to receive live MG and survive to hatch, as well as to survive beyond hatching and to produce antibodies against MG. These studies, however, leave questions as to the potential practical application of in ovo vaccination of chickens for protection against MG. The objective behind the current study was to continue to investigate the effects of the in ovo vaccination of a live attenuated FMG vaccine that is ordinarily administered post-hatch in the commercial layer chicken industry. The goals of the current study were to further confirm the hatch success rate reported in the preliminary study but with the use of a larger sample size, and to determine hatchling survival and post-hatch antibody production against MG. Additionally, the effect of sex on the bird's ability to survive the live in ovo FMG vaccine post-hatch was evaluated since straight run birds were reared in this study and males have been found more susceptible against MG infections (Nolan et al., 1998; Yancey et al., 2001 ).
MATERIALS AND METHODS

Incubation and Treatments
Two replicate trials were conducted. Fertile Hy-Line W-36 commercial layer hatching eggs were obtained from 45-wk-old (trial 1) and 56-wk-old (trial 2) MGclean breeder flocks (National Poultry Improvement Plan, 2014). Eggs were set in 26 trays (90 egg capacity) in trial 1 (2340 eggs) and 24 trays (2160 eggs) in trial 2 in a calibrated single-stage NMC2000 NatureForm Incubator (NatureForm Incubator Company, Jacksonville, FL) set at 37.5
• C and a 53% relative humidity (29.01
• C wet bulb). The same incubator was used in both trials. Eggs were assigned 1 of 6 treatments at the time of set (4 replicate trays assigned to each treatment). All in ovo injection treatments were administered at 18 d of embryo age. The treatments were placed in all levels of the incubator. Treatments included a non-injected embryo control, control diluent only-injected (Poulvac Marek's diluent, Zoetis, Exton, Pennsylvania), and an injection with 1 of 4 dilutions of the Poulvac Myco F vaccine (Zoetis, New York, New York). The FMG vaccine was resuspended and diluted in 50 mL Marek's disease vaccine diluent. The highest dose was taken directly from the non-diluted resuspended vaccine, then a 10 −2 dilution was injected, a 10 −4 dilution, and the lowest dose was a 10 −6 dilution. The 2 extra trays set in trial 1 contained additional control (non-injected) treatment eggs.
Clear eggs and eggs containing dead embryos were removed at both 12 and 18 d of incubation so that only live embryonated eggs were in ovo vaccinated. The eggs were hand-injected with a 50 μL injection volume of their respective injection treatment following the procedures of the "Manual in ovo Vaccination Guide" by Embrex Inc. (2002) . The FMG vaccine was plated prior to and after injections on Frey's Mycoplasma agar (Frey et al., 1968) and incubated at 37
• C for at least 5 d to confirm vaccine viability and CFU administered per dose. A total of 52 eggs in trial 1 and 48 eggs in trial 2 (2 eggs per each tray) were injected with Coomassie brilliant blue R-250 dye (Genlantis, San Diego, CA) at the time of injection and were immediately euthanized. These eggs were opened to determine the location of the injected dye as well as to distinguish the developmental stage of the embryo using an embryo staging system developed by Embrex, Inc. (Avakian, 2006) .
After injection of each treatment, the eggs were placed in plastic hatching baskets (76.2 cm width, 71.1 cm length, and 11.4 cm deep) each of which consisted of 2 trays of the same treatment with a divider between the trays. Mycoplasma gallisepticumvaccinated eggs and control (non-injected and diluentinjected) eggs were hatched in separate incubators in both trials to prevent potential horizontal transmission of the bacteria to the control chicks. The incubators were located in the same room and were outfitted with a fan and filter to shunt exhausted air from the incubators outside of the hatchery. In the first trial, the control eggs were placed in the alternate incubator and the MG-injected eggs were hatched in the original incubator where they spent their first 18 d of incubation. The treatments were reversed in the second replicate trial to eliminate a potential hatcher effect. The hatch baskets that contained FMG-injected eggs were stacked in the hatcher with the lower doses stacked above the higher dosages in order to limit a potential horizontal spread of bacteria due to the movement of fecal droppings to the lower levels. The incubators were set at 36.7
• C and a 53% relative humidity (28.33
• C wet bulb) during the hatch period.
Hatch Sampling
The hatched chicks were removed from their respective incubators at 22 d of incubation. Control chicks were removed before the chicks that received an MG injection treatment. All hatched chicks were counted and residue eggs were opened to confirm the age when each embryo died (Mauldin and Wilson, 2014) . A subset of 50 randomly selected chicks in each treatment group (selected nearly equally from all replicate trays) were subsequently euthanized using carbon dioxide. Each chick was weighed individually, and their yolk sac and its contents were removed and weighed. The yolk sac and its contents were dried at 65
• C for 5 d until weight loss ceased, after which they were reweighed. A total of 32 chicks per treatment (selected equally from all replicate trays) were swabbed down the trachea through the larynx post-mortem for detection of the presence of FMG, using 1.98 mm diameter sterile swabs (Puritan Sterile Rayon Tipped Applicators REF 25-800 R 50, Puritan Medical Products Co LLC, Guilford, ME) pre-wetted in PBS. Each swab sample was suspended in 110 μL of PBS. The extraction and real-time PCR were carried out as indicated by Elliott et al. (2017) . Results were determined on a qualitative basis (positive or negative for MG presence).
Post-Hatch Rearing and Sampling
A subset of birds were reared to 6 wk of age in both trials. Due to the unavailability of the facility used in trial 1, the birds were reared in a different facility in the second trial. In trial 1, the birds were housed in 6 isolation chambers that measured 2.4 m × 2.4 m, where the birds were raised on fresh shavings on the floor and the environment of each chamber was regulated with filtered air. One treatment was assigned to a chamber (no replication) due to the number of chambers in the facility. A total of 85 total chicks were selected from each treatment with a near equal number of chicks selected from each of the replicate trays, so that bird density in each chamber was 0.07 m 2 per bird to meet the recommended growing space for 0-to 8-wk-old Hy-Line W-36 breeders reared on the floor (Hy-Line Red Book, Hy-Line International 2014).
In trial 2, the birds were reared in a different facility containing isolation units that were 0.65 m wide and 1.4 m long in dimension, with plastic slat flooring with an individual water lagoon below the slats for each isolation unit (Branton and Simmons, 1992) . Paper was placed in the units for the first 3 wk until the birds were large enough to stand on the holes in the plastic slating. Thirty chicks were placed in each of 2 replicate isolation units per treatment, which provided a stocking density of 0.03 m 2 per bird. This met the recommended colony cage space requirement for W-36 breeder pullets and cockerels that are reared comingled during the growing period (Hy-line Red Book, Hy-Line International, 2014). In each unit there was near equal bird representation from each incubation tray. Stocking density differences between trials was a result of the maximization of bird numbers, while staying within an acceptable level in the 2 different rearing systems. In both trials, feed and water were provided ad libitum during the 6-wk grow-out period. The feed provided was a mashed layer pullet starter diet that was formulated to meet or exceed NRC requirements (NRC, 1994) . Water was provided through a nipple water line in trial 1 and in a continuously flowing bell waterer in trial 2. Lighting was provided according to the Hy-Line lighting program for 0-to 6-wk-old Hy-Line W-36 pullets housed in a black-out facility (Hy-Line Red Book, Hy-Line International 2014). The lighting program started with 21 h of light with 3 h of dark for the first wk, and light duration was decreased by 1 h each wk. Brooding temperatures followed the recommendations set by Hy-Line (Hy-Line Red Book, Hy-Line International 2014). Floor temperature started between 33 and 35
• C and was decreased by 2 to 3
• C per wk. Mortality was recorded daily and all dead birds were necropsied for determination of the apparent cause of death. The chambers in trial 1 were opened once daily and the isolation units in trial 2 were opened only to remove any dead birds and to add feed and water when needed. Bird well-being was monitored through a window in each unit. The chambers and units containing control and diluent birds were checked first each day. The FMG treatments were then sequentially checked from lowest to highest dose in both trials.
At 6 wk of age, all birds in each unit were swabbed in the choanal cleft for detection of the presence of FMG via PCR using the same protocol as for tracheal swabs of hatched chicks (Branton et al., 1984) . The birds were also bled to test for IgM and IgG antibody production by serum plate agglutination (SPA) and ELISA, respectively. Serum plate agglutination testing with MG antigen (Charles River Laboratories International, Wilmington, MA) was performed using the 0 to 3 scale as in Evans et al. (2007) . Positive SPA tests included scores of 1 or higher. ELISA tests were carried out by an independent laboratory utilizing IDEXX MG antibody testing (IDEXX Laboratories, Westbrook, ME).
Following collection of the blood and swab samples, all birds were weighed individually and then euthanized. All bird incubation, rearing, and handling practices were approved by a USDA-ARS Animal Care and Use Committee (Mississippi State, MS).
Statistical Analysis
The results of the 2 trials were pooled and analyzed using the mixed model procedure of SAS (Version 9.4, SAS Institute Inc., 2014) in order to evaluate the effects of the treatment with trial and each isolation unit or chamber considered as random effects. Sex effect was also analyzed for post-hatch BW and the ELISA titers. Each tray was designated as the experimental unit for all hatch data and each isolation unit or chamber was the experimental unit for all post-hatch data. Mycoplasma gallisepticum detection using PCR and MG-antibody detection from the SPA and ELISA tests were analyzed based on the percentage of birds in each tray (hatch) or isolation unit or chamber (6-wkold birds) that tested positive. Since control and diluent treatments tested negative for MG detection and antibody production, as expected, they were eliminated from the MG and antibody detection analyses in order to compare the percentage of positive birds among the MG treatments. Any P values less than or equal to 0.05 were regarded as significant and significant differences were compared using Fisher's least significant difference.
RESULTS AND DISCUSSION
Injection and Hatch Results
The results of this study show that injecting live strain FMG into embryonated chicken eggs can have large repercussions for the bird, depending on the dosage of FMG administered.
Plate counts of the vaccine plated immediately prior to the vaccination of a 10 −4 dilution averaged 97.5 CFU/20 μL in trial 1 and averaged 53.5 CFU/20 μL in trial 2. The calculated MG counts for each 50 μL dose are presented in Table 1 . The FMG injection treatments will henceforth be referred to according to the CFU results per dose. The highest dose will be referred to as the 1 × 10 6 dosage, the 10 −2 dilution will be referred to as the 1 × 10 4 dosage, the 10 −4 dilution is the 1 × 10 2 , and the lowest dose (10 −6 dilution) is 1x. The average embryo stage score in trial 1 was 1.75 ± 0.08, and in trial 2 was an average score of 2 Treatments were a dilution (using Poulvac Marek's Diluent) of a live attenuated FMG vaccine (Poulvac Myco F). The 1000 dose vaccine vial was resuspended in 50 mL diluent and administered as a 50 μL dose for the non-diluted dose treatment.
2.02 ± 0.06. This indicated that most embryos in both trials at 18 d of incubation were not yet oriented for hatching (the embryo's head was not yet located under the wing) and the yolk stalk and intestines had been retracted into the body cavity, but the external yolk sac still possessed a bilobed shape. The dye injection of 52 embryos in trial 1 indicated that the majority of injections (71.2%) were administered in the amnion, whereas 19.2% were injected into the allantois, and 9.6% of the injections were administered to the embryo intramuscularly (IM). The IM injections were located in the right breast of the embryo with the exception of 1 embryo in trial 1 which received an injection in the muscles under the lower mandible. In trial 2, the dye was located in the amnion in 77.1% of the embryos. Dye was likewise located in the allantois of 14.6% of the embryos, IM in 4.2% of the embryos, and in the air cell of 4.2% of the embryos. All embryos in trial 2 that were injected IM were injected in the right breast muscle. The initial preliminary experiment (Elliott et al., 2017) had majority amnion injections with FMG recovered predominantly in the trachea, but also in the mouth and esophagus, the exterior membrane of the yolk sac, and in the duodenal loop in chicks in all FMG dosages indicating that the mainly amnion injection seems to allow FMG access throughout the chick to the intestinal tract, but was dominantly found in the respiratory tract. Injecting embryos at a later age with a reduced amnion increases the amount of embryo body injections in comparison to amnion injections (Avakian, 2006) . How a body injection of FMG (intramuscular, subcutaneously, or within the body cavity) would affect the embryo and the post-hatch chick in comparison to the amnion injection, which theoretically allows for a more widespread internalization of the bacteria throughout the embryo as the embryo ingests the amnion prior to hatch, is unknown for FMG. Mycoplasma gallisepticum has been found to have a preference for attaching to the surface of the trachea (Cummings and Kleven, 1986; Kleven et al., 1998 Levisohn and Kleven, 2000) , thus the amnion injection may potentially increase the infection of the bird and potentially promote a greater immune response as opposed to a body in ovo injection. a-c Means with differing superscripts within a row are significantly different (P < 0.05) detected by least squared means. 1 Embryonic mortality includes mortality/residue egg categories from day 18 to 22 of incubation. The categories defined are as follows: hatch (embryos that survived to successfully hatch and were alive when removed from the hatcher), dead chicks are chicks that survived to fully hatch yet were found dead when removed from the hatcher, dead pips are embryos that externally pipped through the eggshell yet died before fully emerging from the shell, live pips are embryos that externally pipped yet did not fully exit the eggshell and were found alive when removed from the hatcher, middle dead embryos are any embryos from day 7 to 13 of incubation that were missed during 12 and 18 d candling, late deads are embryos age 14 to 22 d of incubation that did not externally pip and were found dead when removed from the eggshell, cracked eggs are embryos that died due to drying down from a previously cracked egg, contaminated eggs are embryos that died due to contamination, cull chicks are chicks that hatched and were alive when removed from the hatcher yet were unable to survive such as protruding internal organs or major inability to walk, embryos live in the shell are embryos age 18 to 22 d of incubation that had not externally pipped when removed from the hatcher yet were found alive when removed from the eggshell.
2 Embryonated eggs were injected at 18 d of incubation with either Marek's diluent or a dosage of Poulvac Myco F: plated dosage (CFU) is represented for each treatment, diluent eggs were injected with only Marek's diluent, and control eggs were not injected.
3 All percentages are based off the number of embryos determined live at 18 d of incubation by candling. Percentages are based on a total of 50 trays and 4,060 embryos in ovo vaccinated from 2 trials.
Across trials, percentage hatchability of eggs that contained live embryos at 18 d of incubation was lower in the 1 × 10 6 dose treatment (Table 2) . Percentage hatchability of live embryonated eggs in all other treatments did not differ from that of non-injected eggs. The hatch results of this study, with a larger sample size, confirm those found in the previous preliminary trial (Elliott et al., 2017) with the exception of an increased hatch success in the 1 × 10 2 and 1 × 10 4 dosage treatments in the current study. Both studies, however, are in agreement that the 1 × 10 6 CFU dose causes a significant reduction in hatch with roughly 60% survival rate upon removal from the hatcher. The chicks in the 1 × 10 6 dose treatment group that did not survive the hatching period either died after externally pipping or hatching (Table 2 ). This may be due to the extra exertion required by the emerging chick during the hatching process coupled with the large bacterial challenge. A potential limitation of oxygen availability due to the respiratory effects of FMG may also have contributed to this heightened mortality in the 1 × 10 6 CFU dose group.
Of the 32 chicks sampled from each of the MG treatments in each trial, a positive relationship was confirmed between FMG dosage treatment and FMG tracheal colonization (Table 3) . Strain F MG was detected in the trachea of chicks at hatch in each of the treatments that received a dosage of MG in ovo with no MG detected in chicks belonging to the non-injected or diluent-injected treatment groups. The 1 × 10 6 , 1 × 10 4 , and 1 × 10 2 CFU dose treatments had the highest percentage of chicks with detectable levels of FMG in their tracheas. Chicks in the 1x CFU dose treatment had the lowest percentage of chicks (39.1%) that tested positive for FMG in the trachea.
Of the 50 chicks sampled per treatment (n = 600 chicks over both trials), there was no treatment effect on chick weight (P = 0.819), fresh yolk weight (P = 0.445), yolk-free chick weight (P = 0.858), dry yolk weight (P = 0.321), and fresh and dry yolk weights as percentages of chick weight (P = 0.333 and P = 0.247, respectively). The percentage of water in the yolk sac and its contents was not different between treatments (P = 0.262). In the previous preliminary trial (Elliott et al., 2017) , there was a greater moisture content of the yolk sac and its contents in the higher FMG in ovo dosage groups. The lack of replication of this finding may be due to the shorter duration (24 h) that the chicks remained in the hatcher in the current study than in the previous (Elliott et al., 2017) study.
Post-Hatch Mortality
Although embryos that received an FMG in ovo vaccination were able to survive to hatch, FMG clearly had major effects on the chicks after hatch. During posthatch rearing, all FMG in ovo-vaccinated groups experienced higher mortality than did controls. The majority of the mortality occurred during the first 2 wk of post-hatch age in both trials (Figure 1 ) and the level of mortality was dose dependent. Mortality on the first day after placement was elevated in the 1 × 10 6 CFU dose treatment. In turn, on the second day, mortality in the 1 × 10 4 CFU dose treatment group was greatest. On the third day after placement, the first mortality in the 1 × 10 2 CFU dose group occurred in trial 1. 2 Chicks swabbed in the trachea at hatch for detection of strain F Mycoplasma gallisepticum (FMG) tested with PCR: n = 64 chicks per treatment (32 in each of 2 trials).
3 Birds swabbed in the choanal cleft at 6 wk of age for the detection of FMG; n = 1 unit per treatment in trial 1 and 2 units per treatment in trial 2 containing surviving birds at 6 wk of age. Each unit in trial 1 originally started with 85 birds, each unit in trial 2 originally started with 30 birds each.
4 Birds bled at 6 wk of age for serum plate agglutination (SPA) testing for detection of IgM antibodies against MG; n = 1 unit per treatment in trial 1 and 2 units per treatment in trial 2 containing surviving birds at 6 wk of age. Each unit in trial 1 originally started with 85 birds, each unit in trial 2 originally started with 30 birds each.
5 Birds bled at 6 wk of age for ELISA testing for detection of IgG antibodies against MG; n = 1 unit per treatment in trial 1 and 2 units per treatment in trial 2 containing surviving birds at 6 wk of age. Each unit in trial 1 originally started with 85 birds, each unit in trial 2 originally started with 30 birds each.
6 Control and diluent treatments were not included in the analysis due to all negative (zero) results, as expected, to allow for comparisons between MG treatments.
In trial 2, the first mortality in 1 × 10 2 CFU dose group occurred on the second day and mortality percentages increased through 4 d post-hatch. Mortality in the 1x CFU dose group peaked at 5 d of age in trials 1, and at 5 and 6 d of age in trial 2, but at a much lower percentage than in the higher FMG dose groups. Over the total 6-wk post-hatch period, no control birds died in either trial. Only 1 diluent-injected chick died in trial 1 (on d 5 post-hatch) which brought total mortality to 1.2% in the diluent treatment in trial 1. No diluent-injected birds died in trial 2. During the first 2 wk, birds in the 1x CFU dose group experienced a 3.5% mortality in trial 1 and a heightened mortality (11.7%) in trial 2. Mortality in the 1 × 10 2 CFU treatment group was 52.4% during the first 2 wk in trial 1 and was 55.0% during the first 2 wk in trial 2. Mortality in the 1 × 10 4 CFU dose group was 72.9% in trial 1 and was 76.7% in trial 2. Nearly all birds in the 1 × 10 6 CFU dose treatment died during the first 2 wk post-hatch in both trials (88.2% mortality in trial 1 and 90.0% mortality in trial 2). After 13 d post-hatch, only 2 more birds died in trial 1. One bird in the 1 × 10 2 CFU dose group died on day 14 and another one in the 1 × 10 6 CFU dose group died on day 20. No birds died from day 21 to 42 in trial 1. In trial 2, 3 further birds died after 13 d of age. One bird in the 1 × 10 6 CFU dose and one 1 × 10 2 CFU dose bird died on day 14 and 1 bird in the 1 × 10 2 CFU dose group died on day 22. No other mortalities occurred after d 22 of age through the end of the study at 42 d of age. The mortality in the FMG treatments could be due to the initial MG challenge introduced to the embryo and/or in part to the replication of MG within the bird, overpowering the bird's immune system.
All dead birds were necropsied. Out of all the 1 × 10 4 CFU and 1 × 10 6 CFU dose treatment group mortalities on day 1 post-hatch, 78.8% in trial 1 and 93.3% in trial 2 had congested lungs. Of the chick mortalities in the 1 × 10 6 CFU dose treatment beginning on the first day in trial 1, 7% also exhibited hemorrhaging in the lungs, although this hemorrhaging was not seen in trial 2. Birds in the 1 × 10 6 CFU and 1 × 10 4 CFU dose treatments that died on the first day already had feed present in their gizzards (78.8% in trial 1 and 43.3% in trial 2). Ultimately, flecks of caseous exudate were visible in the air sacs of dead chicks from all FMG treatment groups, which were initially found in chicks belonging to the 1 × 10 4 CFU and 1 × 10 6 CFU dose treatments. In trial 1, caseous exudate was first found at 4 d of age in 37.5% of the dead birds in the 1 × 10 4 CFU dose treatment and in 25.0% of the dead birds in the 1 × 10 6 CFU dose treatment. In trial 2, caseous exudate was found earlier in birds that died on the first day of age. This occurred in 22.2% of the dead birds in the 1 × 10 4 CFU dose treatment and in 50.0% of the dead birds in the 1 × 10 6 CFU dose treatment. These trends continued in all the dead birds belonging to the FMG treatments with the majority of birds exhibiting feed in the crop and the gizzard and with caseous exudate occurring predominantly in their air sacs. The 1 diluent-injected bird that died in trial 1 on day 5 posthatch did not have congested lungs or caseous exudate present in its air sacs. That bird had no feed in its crop or gizzard and appeared emaciated.
Thus, in conclusion, the 1 × 10 2 , 1 × 10 4 , and 1 × 10 6 CFU FMG dosages caused mortality to reach an unacceptable rate with only the 1x CFU dose treatment experiencing a low level of mortality. However, this lowest FMG dose mortality was nevertheless elevated in comparison to that of the control and diluentinjected treatments. The significant variation in mortality in the 1x CFU dose between the 2 trials may be due to chance since the number of birds raised was decreased in trial 2, where 1 bird mortality added 1.2% to the total mortality level in trial 1 and 1.7% in trial 2. The birds that died from the FMG injection had full digestive tracts, indicating that even near their time of death, as a result of the FMG bacterial load, the birds felt well enough to consume feed. Our hypothesis for the cause of death is respiratory distress or asphyxiation, since many chicks in the 1 × 10 4 CFU and 1 × 10 6 CFU dosage groups were observed to exhibit extended neck breathing or gasping for air. This behavior was observed when chicks in the 1 × 10 4 CFU and 1 × 10 6 CFU dose groups were removed from the hatcher, as was also observed in chicks from the 1 × 10 4 CFU and 1 × 10 6 CFU dose treatments in the previous experiment (Elliott et al., 2017) . It is of interest to note that birds in the 1 × 10 6 CFU dose treatment of this study exhibited clinical signs like those reported by Power and Jordan (1976) , who injected embryos with an S6 strain of MG in the yolk sac at 18 d of incubation. Power and Jordan (1976) noted that their chicks "gasped intermittently," and the chicks that eventually died during the first week had lungs that were "oedematous and congested," with yellow-colored exudate present in their air sacs, as was found upon necropsy in the current study.
Further research would be needed to determine how to diminish the mortality level of the lowest FMG tested in this study. Using a further attenuated strain of MG for in ovo vaccination, such 6/85 or ts-11 or further attenuating the Poulvac Myco F through further passage levels could potentially reduce the mortality level of the birds. Diminishing the dose even further has a potential to reduce mortality as well, although with such few bacteria already in the vaccine (1x CFU per dose) administered to each egg, the concern would be missing eggs with the vaccine in that lowering the dose may then lower the percentage of birds that receive a dose of the bacteria. Additionally, evaluating the level of protection and immune response of the birds vaccinated in ovo with another strain of MG or with a further attenuated FMG would need to be accessed.
Post-Hatch Body Weight and Immune Response
The BW of the remaining living birds at 6 wk of age (n = 322 in trial 1 and 216 birds in trial 2) was on average 86.7 g heavier for males than for females (P < 0.0001), and BW was reduced with increasing dosage of FMG (Table 4 ; P < 0.0381), which is also in agreement with the experimental results of Power and Jordan (1976) .
Although BW was reduced at 6 wk, even in the 1x CFU FMG dose, the results of this study confirmed that an immune response is possible in a 6-wk-old bird when an FMG vaccine is administered in ovo at 18 d of incubation. Detection of FMG in the choanal cleft, and of serum IgM and IgG antibodies at 6 wk of age post-hatch are presented in Table 3 . In trial 1, 1 diluentinjected bird tested positive for IgM antibody production against MG, but did not test positive for MG by real-time PCR or for IgG antibody production. There were no differences in the percentages of birds positive for FMG between the FMG treatments at 6 wk of age for FMG according to tests from the choanal cleft swabs using PCR (P = 0.86), or IgM (P = 0.47) or IgG antibody production against MG (P = 0.40). The percentage of positive birds in the 1 × 10 4 CFU and 1 × 10 6 CFU doses was numerically lower at 6 wk than at hatch, perhaps due to the low number of surviving birds by 6 wk of age in these treatments. Other potential reasons for the decline may be if the bird is able to clear the bacteria from certain tissues, such as the respiratory tract, better than other infected tissues in the body (Much et al, 2002) . Only the choanal cleft was swabbed at 6 wk, so MG could potentially be present in the bird but absent from the upper respiratory tract at 6 wk. Also, potentially, strain F may possess the ability of other MG strains to invade non-phagocytic cells and avoid detection from swabbing in that manner (Winner et al., 2000) .
Approximately half of the birds in the 1x CFU dose treatment group (46.3% in trial 1 and 64.2% in trial 2 based on an individual bird basis) produced serum IgM. The layer industry considers a vaccination adequate when 50% or more of sampled birds test SPA positive 6 wk post-vaccination . By this definition, the in ovo vaccination of layer chickens with even the lowest dosage tested would be considered as being a successful vaccination. However, this definition is based upon the vaccination of birds during the pullet rearing period (at approximately 9 wk of age with testing near 15 wk of age). The in ovo-vaccinated birds of this study achieve antibody production against MG much earlier in life than do those subjected to the current industry MG vaccination regimen. How this level and timing of MG antibody production compares with those in response to a conventional post-hatch vaccination and associated challenge scenario is unknown. This earlier immune response may have potential benefits by limiting stress on the birds at an already physiologically stressful period (near time of movement to the laying facility and the onset of photostimulation and egg laying).
IgG titers (Table 5) were not significantly different between the treatments (0.079); however, when sex was included as a fixed effect in the analysis, there was a significant treatment (in ovo injection treatment) × sex interaction (P < 0.0001). Nevertheless, within the control, diluent, 1x CFU, and 1 × 10 6 CFU dose treatment groups, there was no significant difference between the sexes for IgG antibody production. In the 1 × 10 2 CFU FMG dose treatment, males had a greater production of IgG, but in the 1 × 10 4 CFU dose treatment, females had a greater IgG production. Mycoplasma gallisepticum has been found to have a more pronounced effect on males than females in house finches (Nolan et al., 1998) . Other mycoplasma infections, such as Mycoplasma pulmonis, have also been found to be more severe in male mice than in female mice, which is reduced in severity when the testes are removed (Yancey et al., 2001) . The results of this study suggest that, at least in surviving birds, sex does not seem to influence antibody production in chickens subjected to an FMG challenge at a young age. Dead birds in the current study were not sexed when necropsied, so it cannot be definitively confirmed if one sex succumbed to FMG more than the other. However, the sex ratios of the surviving birds administered FMG were similar in comparison to surviving birds belonging to the control and diluent-injected treatments. The proportion of male and female birds at 6 wk of age in the control and diluent-injected treatments in both trials (288 total birds) were 54.2% and 45.8%, respectively. Of all the birds that received an in ovo injection of FMG and that remained alive at 6 wk of age across both trials (250 total remaining birds), 53.2% were male and 46.8% were female. Since the sex ratios of those birds are similar to the control and diluent-injected treatment birds, this would indicate that males did not possess a predisposed greater sensitivity to an FMG challenge employed by the in ovo vaccination of live FMG.
In conclusion, this study was undertaken to evaluate the post-hatch effects (up to 6 wk of age) of an FMG vaccination during the embryonic period rather than during the pullet-rearing period as a means of protection against MG in layer chickens. Increasing the FMG dosage was found to increase post-hatch mortality and decrease BW gain. Only the lowest FMG dosage tested in these trials exhibited a remotely acceptable posthatch level of mortality. Antibodies against MG were detected in a 6-wk-old bird even when an FMG vaccine at the lowest dose was administered in ovo at 18 d of incubation. These birds that received an in ovo injection of FMG mounted an immune response earlier in life that was more distant to the start of the lay period, which is in contrast to current commercial pullet vaccination practices. How this immune response compares to the current practice of vaccinating pullets at approximately 9 wk of age is uncertain. Further research is needed to evaluate how in ovo and pullet FMG vaccinations compare with regard to their effects on immunocompetence and the protection the layers receive against field-strain MG challenges as well as the subsequent physiological effects on the birds through a laying cycle.
